Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis

Vaccine

Volumn 17, Issue 3, 1999, Pages 291-300

  Mukhopadhyay, Srirupa ^a   Sen, Pradip ^a   Bhattacharyya, Sandip ^b   Majumdar, Subrata ^b   Roy, Syamal ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b BOSE INSTITUTE   (India)

Author keywords

Immunoprophylaxis; Leishmanial parasite; Visceral leishmaniasis

Indexed keywords

LEISHMANIA VACCINE; MEMBRANE PROTEIN; SUPEROXIDE;

AMASTIGOTE; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; HAMSTER; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INOCULATION; INTRACARDIAC DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LEISHMANIA DONOVANI; LIFESPAN; MACROPHAGE ACTIVATION; NONHUMAN; PARASITE INCIDENCE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; VISCERAL LEISHMANIASIS;

EID: 0345337262     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)90017-2     Document Type: Article

References (53)

1. Modabber F, Leishmaniasis. TDR 12th Programme Report 1995, pp. 135-146.
2. Croft S.L. Recent development in the chemotherapy of leishmaniasis. Trends in Pharmacological Science. 9:1988;376-381.
3. Murray H.W., Berman J.D., Wright S.D. Immunochemotherapy for intracellular Leishmania donovani infection: τ interferon plus pentavalent antimony. Journal of Infectious Diseases. 157(5):1988;973-978.
4. Grogl M., Thomason T.N., Franke E.D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. American Journal of Tropical Medicine and Hygiene. 47(1):1992;117-126.
5. Jackson J.E. et al, Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania spp. from patients unresponsive to pentavalent antimony. American Journal of Tropical Medicine and Hygiene. 43(5):1990;464-480.
6. Holbrook T.W., Cook J.A., Parker B.W. Immunisation against Leishmania donovani: glucan as an adjuvant with killed promastigotes. American Journal of Tropical Medicine and Hygiene. 30(4):1981;762-768.
7. Mansohn-Bahr P.E.C. Immunity in kala-azar. Transactions of Royal Society Tropical Medicine Hygiene. 55:1961;550-555.
8. Jarrecki-Black J.C., Glassman B., James E.R. Adoptive transfer of vaccine induced resistance to Leishmania donovani. American Journal of Tropical Medicine and Hygiene. 34:1985;1095-1097.
9. Rachamim N., Jaffe C.L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. Journal of Immunology. 150:1993;2322-2331.
10. Ali N., Afrin F. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. Journal of Parasitology. 83:1997;70-75.
11. Afrin F., Ali N. Adjuvanticity and protectiv immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infection and Immunity. 65:1997;0-00.
12. Liew F.Y., Hale C., Howard J.G. Prophylactic Immunisation against experimental leishmaniasis IV. subcutaneous immunization prevents the induction of protective immunity against fatal L. major infection. Journal of Immunology. 135(3):1985;2095-2101.
13. Etges R., Bouvier J., Bordier C. The major surface protein of Leishmania promastigotes is a protease. Journal of Biology and Chemistry. 261(20):1986;9098-9101.
14. Chamsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infection and Immunity. 52:1988;3272-3279.
15. Russell D.G., Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. Journal of Immunology. 140:1988;1274-1279.
16. Handman E., McConville M.J. Carbohydrate antigens as possible vaccines - a case for the Leishmanial glycolipid. Immunology Today. 8:1987;181-185.
17. Mitchell G.F., Handman E., Spithill T.W. Examination of variables in the vaccination of mice against cutaneous leishmaniasis using living avirulent cloned lines and killed promastigotes of Leishmania major. International Journal of Parasitology. 15(6):1985;677-684.
18. Rivier D., Shah R., Bovay P., Mauel J. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunology. 15:1993;75-84.
19. Gorczynski R.M. Immunization of susceptible BALB/c mice against Leishmania braziliensis II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes. Cellular Immunology. 94:1985;1-10.
20. + T cells which protect susceptible BALB/c mice against infection with virulent L. major. Infection and Immunity. 61:1993;5205-5213.
21. Bretscher P.A.et al. Establishment of stable, cell-mediated immunity that makes 'susceptible' mice resistant to Leishmania major. Science. 257(5069):1992;539-542.
22. Liew F.Y. Role of cytokines in killing of intracellular pathogens. Immunity Letters. 30(2):1991;193-197.
23. Xu D., Liew F.Y. Genetic vaccination against leishmaniasis. Vaccine. 12(16):1994;1534-1536.
24. De Frietas L.A.R., Beverley S.M. Development of a safe, live Leishmania vaccine line by gene replacement. Proceedings of the National Academy of Science USA. 92:1995;10267-10271.
25. Jardim A., Funk V., Caprioli R.M., Olafson R.W. Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochemistry Journal. 305:1995;307-313.
26. Russo D.M., Turco S.J., Burns J.M. Jr., Reed S.G. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins. Journal of Immunology. 148(1):1992;202-207.
27. Jensen A.T.R., Ismail A., Gasim S., Kurtzhals J.A.L., Kemp M., Kharazmi T.T.G. Humoral and cellular immune response/s to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11 (KMP-11). Acta Parasitologica Turcica. 21(Suppl.1):1997;43.
28. Dasgupta S., Ghosh D.K., Majumder H.K. A cloned kinetoplast DNA minicircle fragment from a Leishmania spp. specific for post Kala-azar dermal leishmaniasis strain. Parasitology. 102:1991;187-191.
29. Ray J.C. Cultivation of various Leishmania parasites on solid medium. Indian Journal of Medical Research. 20:1932;355-357.
30. Sanyal T., Gangopadhyay P., Ghosh D.K., Sarkar D. Expression of antigens in virulent and avirulent Indian strains of Leishmania donovani. Journal of Bioscience. 19(3):1994;291-299.
31. Saha B., Roy H., Pakrashi A., Chakraborti R.N., Roy S. Immunobiological studies on experimental visceral leishmaniasis. I. Changes in lymphoid organs and their possible role in pathogenesis. European Journal of Immunology. 21:1991;577-581.
32. Hart D.T., Vickerman K., Coombs G.H. A quick, simple method for purifying L. mexicana amastigotes in large numbers. Parasitology. 82:1981;345-355.
33. Stauber L.A. Host resistance to the Khartoum strain of Leishmania donovani. Rice Institute Pamphlet. 45:1958;80.
34. Grob P.M., David E., Warren T.C., Deleon R.P., Farina P.R., Homon C.A. Characterisation of a receptor for human monocyte derived neutrophil chemotactic factor/IL-8. Journal of Biology and Chemistry. 265:1990;8311-8316.
35. Grunow R., D' Apuzzo M., Wyss-Coray T., Frutig K., Pichler W.J. A cell surface ELISA for the screening of monoclonal antibodies to antigens on viable cells in suspension. Journal of Immunity Methods. 171(1):1994;93-102.
36. Majumder S., Kane L.H., Rossi M.W., Volpp B.D., Nauseef W.M., Korchak H.M. Protein kinase C isotypes and signal transduction in human neutrophils: selective substrate specificity of calcium-dependent beta-PKC and novel calcium-independent nPKC. Biochimica et Biophysica Acta. 1176:1993;276-286.
37. Maniatis T, Fritsch EF, Sambrook J, Molecular cloning; A Laboratory Manual. Cold Spring Harbor, Cold Spring Harbor Laboratory.
38. Chomezynski P., Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry. 162:1987;156-159.
39. Russell D.G., Talamas-Rohana P. Leishmania and the macrophage: a marriage of inconvenience. Immunology Today. 10:1989;328-333.
40. Tolson D.L., Turco S.J., Beecroft R.P., Pearson T.W. The immunochemical strusture and surface arrangement of Leishmania donovani lipophosphoglycan determined using monoclonal antibodies. Molecular Biochemistry and Parasitology. 35:1989;109-118.
41. McNeely T.B., Turco S.J. Requirement of lipophosphoglycan for intracellular survival of Leishmania donovani within human monocytes. Journal of Immunology. 144:1990;2745-2750.
42. Brandonisio O., Panaro M.A., Marzio R., Marangi A., Faliero S.M., Jirillo E. Impairment of the human phagocyte oxidative responses caused Leishmania lipophosphoglycan (LPG): in vitro studies. FEMS Immunology and Medical Microbiology. 8:1994;57-62.
43. Jardim A., Tolson D.L., Turco S.J., Pearson T.W., Olafson R.W. The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex. Journal of Immunology. 147(10):1991;3538-3544.
44. Keithly J.S. Infectivity of Leishmania donovani amastigotes and promastigotes for golden hamsters. Journal of Protozoology. 23:1976;244-245.
45. Giannini S.M. Effects of promastigote growth phase, frequency of subculture and host age on promastigote initiated infections with Leishmania donovani in the golden hamster. Journal of Protozoology. 21(4):1974;521-527.
46. Connell N.D., Medina-Acosta E., Mcmaster R., Bloom B.R., Russell D. Effective immunization against cutaneous leishmaniasis with recombinant Bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proceedings of the National Academy of Science USA. 90:1993;11473-11477.
47. Fortier A.H., Mock B.A., Meltzer M.S., Nacy C.A. Mycobacterium bovis BCG induced protection against cutaneous and systemic L. major infections of mice. Infection and Immunity. 55:1987;1707-1714.
48. Smrkovski L.L., Larson C.L. Effect of treatment of BCG on the course of visceral leishmaniasis in BALB/c mice. Infection and Immunity. 16:1977;249-257.
49. Murray H.W. Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. Journal of Experimental Medicine. 153:1981;1302-1315.
50. Rivier D., Shah R., Mauel J. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and of site of immunization. Acta Parasitologica Turcica. 21(Suppl.1):1997;27.
51. Turco S.J., Descoteaux A. The lipophosphoglycan of Leishmania parasites. Annual Reviews in Microbiology. 46:1992;65-94.
52. Rodrigues V. Jr., Da Silva J.S., Campos-Neto A. Selective inability of spleen antigen presenting cells fron Leishmania donovani infected hamsters to mediate T cell proliferation to parasite antigens. Parasite Immunology. 14:1992;49-58.
53. Fruth V., Solioz N., louis J.A. Leishmania major interferes with antigen presentation by infected macrophage. Journal of Immunology. 150:1993;1857-1864.